Arizona State University researchers claim microbiota transfer therapy reduces symptoms associated with autism and gastrointestinal problems for two years post-treatment. The study suggests MTT may be a promising option for helping to treat children with ASD who also have GI problems. The researchers stress further research, including double-blind, placebo-controlled randomized trials with a larger cohort be carried out.
